1. Scrip
  2. >>Business
  3. >>Earnings

Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Question Of Omecamtiv, Sotorasib Filing Plans Unanswered

 
• By Mandy Jackson

Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.

Abstract mash line and point Question mark. Business illustration. Polygonal low poly
Amgen left questions unanswered regarding sotorasib, omecamtiv and tezepelumab

Amgen, Inc.’s third quarter financials generally met or beat analyst consensus despite COVID-19 impacts on individual product sales and the company essentially maintained its revenue guidance for 2020. However, investors’ biggest questions going into Amgen’s 28 October earnings call about three key late-stage programs remained unanswered.

The company did not say whether it will seek accelerated approval from the US Food and Drug Administration for sotorasib...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

More from Business